Abstract:
Primaquine (PQ) and tafenoquine (TQ) can be used for the radical cure (RC) of P. vivax malaria.
PQ requires a 14-day dose, compared to a single-day dose for TQ, which is likely to improve
patient adherence to the treatment. However, a significant safety concern with both TQ and PQ is
the high risk of acute hemolytic anemia (AHA) in individuals with glucose-6-phosphate
dehydrogenase (G6PD) deficiency. WHO recommends that “the G6PD status of patients should be
used to guide administration of PQ & TQ for preventing relapse. The aim of the study is to
investigate whether it is operationally feasible to provide appropriate radical cure (RC) treatment
after semi-quantitative G6PD testing to P. vivax patients who are eligible for RC based on the
national treatment guidelines
